The following is a summary of the Aurora Cannabis Inc. (ACB) Q4 2024 Earnings Call Transcript:

Financial Performance:

• Net revenue for Aurora Cannabis increased by 21% on a trailing 12-month basis.

• Adjusted gross margin was reported at 49%.

• Positive adjusted EBITDA was achieved in each of the four fiscal quarters, marking the first time Aurora reported annual positive adjusted EBITDA.

• Cash balance ended the year at approximately $180 million.

Business Progress:

• Significant growth in the global medical cannabis business, accounting for 68% of total revenue and 90% of adjusted gross profit for the quarter.

• Acquired remaining 90% equity interest in MedReleaf Australia, strengthening position in Australia's medical cannabis market.

• Introduced new products including premium dried flower products and resin cartridges.

• Entered New Zealand and Switzerland markets, expanding global reach.

• Focused on medical cannabis, leveraging experience and EUGMP certified facilities to target internationally regulated markets.

Opportunities:

• Medical cannabis sector showing robust growth, with only about 1% of the Canadian adult population currently using medical cannabis, indicating significant potential for market expansion.

• Regulatory changes, like those in Germany, which recently descheduled cannabis, could increase patient access and market size, allowing Aurora to capitalize on these developments.

Risks:

• Decline in consumer cannabis revenue due to strategic shift towards higher-margin medical cannabis.

More details: Aurora Cannabis IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.